VolitionRX Limited (NYSEAMERICAN:VNRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

VolitionRX Limited (NYSEAMERICAN:VNRX) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $46.6667.

A number of equities research analysts recently commented on VNRX shares. Benchmark reaffirmed a “hold” rating on shares of VolitionRX in a report on Tuesday. Citigroup lowered shares of VolitionRX to a “hold” rating in a research report on Monday, April 20th. D. Boral Capital restated a “hold” rating on shares of VolitionRX in a research note on Monday, April 20th. Finally, HC Wainwright dropped their price objective on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd.

Institutional Investors Weigh In On VolitionRX

A number of large investors have recently made changes to their positions in VNRX. Jane Street Group LLC acquired a new position in shares of VolitionRX during the 4th quarter worth $28,000. Virtu Financial LLC grew its holdings in VolitionRX by 166.6% in the fourth quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 67,848 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of VolitionRX during the 4th quarter valued at $34,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of VolitionRX during the 2nd quarter worth $52,000. Finally, Citadel Advisors LLC raised its position in shares of VolitionRX by 70.1% in the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after buying an additional 135,775 shares during the period. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

VolitionRX Stock Performance

VNRX stock traded down $0.31 during midday trading on Tuesday, reaching $2.36. The company’s stock had a trading volume of 250,291 shares, compared to its average volume of 290,090. The firm has a market capitalization of $19.66 million, a price-to-earnings ratio of -0.58 and a beta of 1.04. VolitionRX has a 1 year low of $1.91 and a 1 year high of $18.80. The stock has a fifty day simple moving average of $3.06 and a two-hundred day simple moving average of $4.50.

VolitionRX (NYSEAMERICAN:VNRX) last issued its earnings results on Thursday, May 14th. The medical research company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.27). The business had revenue of $0.99 million during the quarter, compared to analyst estimates of $1.52 million. As a group, analysts forecast that VolitionRX will post -2.4 EPS for the current fiscal year.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.